Table 2. Enrolment into HIV care & treatment, WHO stage, median CD4 count, ART-eligibility and start of ART by study site, department, age and sex, Rwanda, 2009.
| Total | Number (%) with 1st visit to ART clinic | Number (%) with WHO stage 3 or 4a,b | Median CD4 count in cells/mm3 (IQR)c | Number (%) of ART-eligible patientsd | Number (%) of patients started ART ≤90 dayse | |
| Total | 482 | 201/482 (41.7) | 28/176 (15.9) | 387 (242–533) | 81/170 (47.7) | 45/81 (55.6) |
| Study site | ||||||
| Muhoza | 154 | 37/154 (24.0) | 6/37 (16.2) | 366 (247–498) | 20/37 (54.1) | 13/20 (65.0) |
| Ruhengeri | 6 | 6/6 (100.0) | 4/6 (66.7) | 264 (97–440) | 5/6 (83.3) | 1/5 (20.0) |
| Gasiza | 17 | 6/17 (35.3) | 3/6 (50.0) | 299 (112–417) | 4/6 (66.7) | 4/4 (100.0) |
| Kibagabaga | 85 | 38/85 (44.7) | 1/28 (3.6) | 431 (258–551) | 9/28 (32.1) | 9/9 (100.0) |
| Kinyinya | 50 | 21/50 (42.0) | 2/18 (11.1) | 381 (96–492) | 6/14 (42.9) | 4/6 (66.7) |
| Kimironko | 99 | 62/99 (62.6) | 8/56 (14.3) | 392 (273–536) | 26/54 (48.2) | 5/26 (19.2) |
| Rwaza | 24 | 12/24 (50.0) | 3/11 (27.3) | 369 (160–388) | 6/11 (54.6) | 4/6 (66.7) |
| Kabuye | 47 | 19/47 (40.4) | 1/14 (7.1) | 588 (288–824) | 5/14 (35.7) | 5/5 (100.0) |
| p-value f | <0.001 | 0.005 | 0.179 | 0.314 | <0.001 | |
| Department | ||||||
| VCT | 293 | 113/293 (38.6) | 15/101 (14.9) | 405 (279–564) | 43/99 (44.3) | 23/43 (53.5) |
| ANC | 99 | 46/99 (46.5) | 1/38 (2.6) | 469 (269–565) | 11/37 (29.7) | 7/11 (63.6) |
| TB | 10 | 7/10 (70.0) | 4/7 (57.1) | 188 (22–340) | 6/7 (85.7) | 2/6 (33.0) |
| OPD | 80 | 35/80 (43.8) | 8/30 (26.7) | 287 (112–387) | 21/29 (72.4) | 13/21 (61.9) |
| p-value f | 0.139 | 0.001 | 0.0002 | <0.001 | 0.644 | |
| Age | ||||||
| 0–4 | 7 | 1/7 (14.3) | N.A. | N.A. | N.A. | N.A. |
| 5–14 | 3 | 2/3 (66.7) | N.A. | N.A. | N.A. | N.A. |
| 15–24 | 121 | 51/121 (42.2) | 4/44 (9.1) | 476 (349–623) | 11/42 (26.2) | 5/11 (45.5) |
| 25–34 | 192 | 79/192 (41.2) | 8/69 (11.6) | 422 (266–583) | 31/68 (45.6) | 15/31 (48.4) |
| 35–44 | 97 | 39/97 (40.2) | 4/35 (11.4) | 344 (146–441) | 18/33 (54.6) | 12/18 (66.7) |
| >45 | 53 | 29/53 (54.7) | 12/28 (42.9) | 325 (192–378) | 21/27 (77.8) | 13/21 (61.9) |
| p-value f | 0.253 | 0.002 | 0.0010 | <0.001 | 0.518 | |
| Sex | ||||||
| Female | 339 | 139/339 (41.0) | 16/120 (13.3) | 412 (259–558) | 48/116 (41.4) | 30/48 (62.5) |
| Male | 143 | 62/143 (43.4) | 12/56 (21.4) | 330 (209–479) | 33/54 (61.1) | 15/33 (45.5) |
| p-value f | 0.632 | 0.171 | 0.0126 | 0.016 | 0.129 |
N.A. Not Applicable; TB Tuberculosis; ANC Antenatal care; HIV Human immunodefiency virus; OPD Outpatient department; VCT Voluntary counselling and testing; ART antiretroviral treatment; IQR interquartile range; WHO World Health Organization.
WHO stage was available for 179. Data provided are for the 176 patients aged 15 years or above.
Patients with pulmonary TB and HIV infection are by definition in WHO stage 3; however not all patients diagnosed at TB clinics were confirmed TB cases.
CD4 count results were available for 188/201. Data provided are on the 185 patients aged 15 years or above.
ART eligibility was based on CD4 count (CD4<350 cells/mm3) and WHO stage (stage 4). Data provided are on the 170 patients aged 15 years or above.
Among those who were eligible for ART. Data provided are on the 81 patients aged 15 years or above.
The p-values are based on chi-squared test, Fisher's exact test or Kruskal-Wallis test, as appropriate.